Followers | 45 |
Posts | 7008 |
Boards Moderated | 0 |
Alias Born | 02/24/2004 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 25, 2017 9:47:25 AM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=36631914
Aastrom Biosciences | Open Studies| Completed
ClinicalTrials.gov
Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Condition: Alveolar Bone Defects
Interventions: Biological: Tissue Repair Cell therapy; Device: Tissue Repair Cells (TRC)
Sponsors: University of Michigan; Aastrom Biosciences
Phases: Phase I / Phase II
Number Enrolled: 24
Funded By: OTHER / INDUSTRY
NCT ID: NCT00755911
Completion Date: March 2010
Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.
Conditions: Fracture, Ununited; Pseudarthrosis
Interventions: Procedure: Fracture surgery; Drug: Cultured Bone Marrow Tissue
Sponsor: Aastrom Biosciences
Phases: Phase I / Phase II
Number Enrolled: 36
Funded By: INDUSTRY
NCT ID: NCT00424567
Completion Date: June 2007
Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
Condition: Single Level Posterolateral Spinal Fusion
Interventions: Procedure: Bone Repair Cells (BRCs) with allogeneic, demineralized bone matrix; Procedure: Spine fusion with autologous bone graft
Sponsor: Aastrom Biosciences
Phases: Phase I / Phase II
Number Enrolled: 2
Funded By: INDUSTRY
NCT ID: NCT00797550
Completion Date: October 2008
Use of Vascular Repair Cells (VRC) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
Condition: Peripheral Arterial Disease
Interventions: Biological: autologous bone marrow cells; Biological: electrolyte solution (without cells)
Sponsor: Aastrom Biosciences
Phase: Phase II
Number Enrolled: 150
Funded By: INDUSTRY
NCT ID: NCT00468000
Completion Date: June 2011
Cardiac Repair Cell (CRC) Treatment of Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
Condition: Dilated Cardiomyopathy
Intervention: Biological: Cardiac Repair Cells (CRCs)
Sponsor: Aastrom Biosciences
Phase: Phase II
Number Enrolled: 40
Funded By: INDUSTRY
NCT ID: NCT00765518
Completion Date: June 2010
UPDATE: Tuesday March 3, 2009,
FDA Removes Clinical Hold From Aastrom Phase II IMPACT-DCM Clinical Trial
“… patient enrollment would resume in all four clinical sites and expects to complete it by the end of the year.
Activation of the fifth clinical site is underway.”
Bone Repair Cell (BRC) Treatment of Patients With Osteonecrosis of the Femoral Head
Condition: Osteonecrosis
Intervention: Procedure: Core decompression
Sponsor: Aastrom Biosciences
Phase: Phase III
Number Enrolled: 120
Funded By: INDUSTRY
NCT ID: NCT00505219
Completion Date: June 2011
Recent VCEL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:05:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 08:13:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 08:18:41 PM
- Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024 • GlobeNewswire Inc. • 06/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:05:33 PM
- Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024 • GlobeNewswire Inc. • 05/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:07:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:05:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2024 04:15:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:05:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 02:43:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 05:10:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 12:59:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:10:26 PM
- Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance • GlobeNewswire Inc. • 05/08/2024 11:55:00 AM
- Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 08:15:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:08:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:07:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 10:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 08:35:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 02:04:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:04:33 PM
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance • GlobeNewswire Inc. • 02/29/2024 12:55:00 PM
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM